Eligibility Criteria:
1. History of 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1
a. Participants with a diagnosis of chronic migraine who report having 4 to 10 migraine days per month with moderate to severe headache pain in each month of the 3 months prior to Visit 1 due to concomitant preventive treatment are allowed in the study
2. Participant is currently prescribed ubrogepant and has been using ubrogepant for at least 3 months for the acute treatment of migraine in adults, according to the FDA-approved indication
3. Participant reports at least 1 migraine attack treated during prodrome in the 4 weeks prior to Visit 1 based on recall
4. By history and investigator’s judgement, participant routinely experiences prodrome symptoms (early warning signs that signal the beginning of a migraine such as fatigue, neck pain/stiffness, mood changes, sensitivity to light/sound/ nausea or dizziness) that are reliably followed by a headache of any intensity
5. Adult participants with current clinical diagnosis of migraine or chronic migraine according to ICHD-3
6. Participant has access to a mobile device compatible with the e-Diary